These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32194011)

  • 21. Opening the Policy Window to Mobilize Action Against Corruption in the Health Sector Comment on "We Need to Talk About Corruption in Health Systems".
    Mackey TK
    Int J Health Policy Manag; 2019 Nov; 8(11):668-671. PubMed ID: 31779293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan.
    Al-Abbadi I; Qawwas A; Jaafreh M; Abosamen T; Saket M
    Clin Ther; 2009 Jun; 31(6):1335-44. PubMed ID: 19695398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [COUNTERACTION TO CORRUPTION DURING PUBLIC PROCUREMENT OF MEDICINAL PRODUCTS].
    Lohvynenko B; Podoliaka A; Domin Y; Kolesnikova I; Salaieva K
    Georgian Med News; 2022 Feb; (323):175-179. PubMed ID: 35271492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers.
    Garuba HA; Kohler JC; Huisman AM
    Global Health; 2009 Oct; 5():14. PubMed ID: 19874613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing corruption in humanitarian assistance: perceptions, gaps and challenges.
    Maxwell D; Bailey S; Harvey P; Walker P; Sharbatke-Church C; Savage K
    Disasters; 2012 Jan; 36(1):140-60. PubMed ID: 21623891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corruption in Anglophone West Africa health systems: a systematic review of its different variants and the factors that sustain them.
    Onwujekwe O; Agwu P; Orjiakor C; McKee M; Hutchinson E; Mbachu C; Odii A; Ogbozor P; Obi U; Ichoku H; Balabanova D
    Health Policy Plan; 2019 Sep; 34(7):529-543. PubMed ID: 31377775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction.
    Cohen JC; Mrazek M; Hawkins L
    Clin Pharmacol Ther; 2007 Mar; 81(3):445-9. PubMed ID: 17251983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of corruption, democratic accountability, and effectiveness of HIV/AIDS official development assistance.
    Lee HY; Yang BM; Kang M
    Glob Health Action; 2016; 9():30306. PubMed ID: 27189199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disclosure, transparency, and accountability: a qualitative survey of public sector pharmaceutical committee conflict of interest policies in the World Health Organization South-East Asia Region.
    Grundy Q; Parker L; Wong A; Fusire T; Dimancesco D; Tisocki K; Walkowiak H; Vian T; Kohler J
    Global Health; 2022 Mar; 18(1):33. PubMed ID: 35303902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of corruption and governance in the delivery of frontline health care services in the public sector: a scoping review of current and future prospects in low and middle-income countries of south and south-east Asia.
    Naher N; Hoque R; Hassan MS; Balabanova D; Adams AM; Ahmed SM
    BMC Public Health; 2020 Jun; 20(1):880. PubMed ID: 32513131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance.
    Vian T; Kohler JC; Forte G; Dimancesco D
    J Pharm Policy Pract; 2017; 10():18. PubMed ID: 28588896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring corruption in the South African health sector.
    Rispel LC; de Jager P; Fonn S
    Health Policy Plan; 2016 Mar; 31(2):239-49. PubMed ID: 26104821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The sustainable development goals as a framework to combat health-sector corruption.
    Mackey TK; Vian T; Kohler J
    Bull World Health Organ; 2018 Sep; 96(9):634-643. PubMed ID: 30262945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Governance in managing public health resources in Brazilian municipalities.
    Avelino G; Barberia LG; Biderman C
    Health Policy Plan; 2014 Sep; 29(6):694-702. PubMed ID: 23411119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. E-Government Attempts in Small Island Developing States: The Rate of Corruption with Virtualization.
    Sari A
    Sci Eng Ethics; 2017 Dec; 23(6):1673-1688. PubMed ID: 27995444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.
    Nsimba SE
    East Afr J Public Health; 2008 Dec; 5(3):205-10. PubMed ID: 19374325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Good governance and corruption in the health sector: lessons from the Karnataka experience.
    Huss R; Green A; Sudarshan H; Karpagam S; Ramani K; Tomson G; Gerein N
    Health Policy Plan; 2011 Nov; 26(6):471-84. PubMed ID: 21169338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. For a honest Maghreb care system. Systematic Review of the International Literature on Corruption in the Health care System.
    Kacem M; Melki S; Nouira S; Khelil M; Sriha Belguith A; Ben Abdelaziz A
    Tunis Med; 2019 Mar; 97(3):397-406. PubMed ID: 31729714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promoting anti-corruption, transparency and accountability to achieve universal health coverage.
    Koller T; Clarke D; Vian T
    Glob Health Action; 2020; 13(sup1):1700660. PubMed ID: 32194009
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessing national governance of medicine promotion: an exploratory study in Ghana to trial a structured set of indicators.
    McLean M; Kohler JC; Edwards D
    J Pharm Policy Pract; 2019; 12():26. PubMed ID: 31508235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.